Structures by: Rayni I.
Total: 9
1-{[3-(Thiophen-2-yl)-4,5-dihydro-1,2-oxazol-5-yl]methyl}-2,3-dihydro-1<i>H</i>-indole-2,3-dione
C16H12N2O3S
IUCrData (2017) 2, 3 x170315
a=7.3834(2)Å b=11.7331(3)Å c=16.9144(4)Å
α=90° β=101.7310(10)° γ=90°
1-(Prop-2-en-1-yl)-3-[(prop-2-en-1-yl)oxy]quinoxalin-2(1<i>H</i>)-one
C14H14N2O2
IUCrData (2017) 2, 5 x170656
a=8.4015(6)Å b=9.0041(6)Å c=9.1465(7)Å
α=114.214(3)° β=101.275(4)° γ=90.978(3)°
(4<i>Z</i>)-4-(2-Oxopropylidene)-1,3-bis(prop-2-en-1-yl)-2,3,4,5-tetrahydro-1<i>H</i>-1,5-benzodiazepin-2-one
C18H20N2O2
IUCrData (2017) 2, 4 x170493
a=8.6864(6)Å b=8.9925(6)Å c=10.9872(7)Å
α=110.6530(10)° β=95.1110(10)° γ=104.7230(10)°
1,4-Dihexyl-1,2,3,4-tetrahydroquinoxaline-2,3-dione
C20H30N2O2
IUCrData (2017) 2, 7 x171019
a=13.357(3)Å b=9.209(2)Å c=16.743(4)Å
α=90° β=113.277(3)° γ=90°
1,4-Di-<i>n</i>-octyl-1,2,3,4-tetrahydroquinoxaline-2,3-dione
C24H38N2O2
IUCrData (2017) 2, 4 x170520
a=26.4070(10)Å b=14.3718(5)Å c=12.9624(5)Å
α=90° β=108.312(2)° γ=90°
2-(1-Hexyl-2-oxo-2,3-dihydro-1<i>H</i>-indol-3-ylidene)propanedinitrile
C17H17N3O
IUCrData (2017) 2, 5 x170706
a=12.0350(5)Å b=24.5052(9)Å c=4.9909(2)Å
α=90° β=90° γ=90°
4-(2-Oxopropylidene)-1,3-bis(prop-2-yn-1-yl)-2,3,4,5-tetrahydro-1<i>H</i>-1,5-benzodiazepin-2-one
C18H16N2O2
IUCrData (2016) 1, 6 x161013
a=8.6905(2)Å b=9.0249(3)Å c=10.8240(3)Å
α=68.8030(10)° β=78.5200(10)° γ=72.9800(10)°
2-(1-decyl-2-oxoindolin-3-ylidene)propanedinitrile
C21H25N3O
Acta Crystallographica Section E (2019) 75, 1 21-25
a=44.4837(12)Å b=4.72930(10)Å c=18.3432(5)Å
α=90° β=106.965(2)° γ=90°
1-Nonyl-2,3-dihydro-1<i>H</i>-indole-2,3-dione
C17H23NO2
Acta Crystallographica Section E (2019) 75, 8 1140-1144
a=16.2512(4)Å b=7.6859(2)Å c=13.0989(3)Å
α=90° β=106.6400(10)° γ=90°